Intended for US Healthcare Professionals Only

Take control of von Willebrand disease

wilate® is a VWF/FVIII complex indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes.

wilate® has the most extensive von Willebrand disease (VWD) indication profile among VWF-containing products, across the full pediatric and adult population.

wilate® is a high-purity plasma-derived von Willebrand factor and coagulation factor VIII (VWF/FVIII) complex

wilate® was developed specifically for people with VWD, and contains VWF and 
FVIII in a physiological 1:1 activity ratio, which may facilitate simple dosing and monitoring even when repeated dosing is needed.4,5

The purification process includes two virus inactivation steps to help ensure a high-purity product free of viral contamination.4

Over 15 years of clinical and real-life experience have proven the efficacy and tolerability of wilate® in people with all types of von Willebrand disease for surgery, on-demand treatment and prophylaxis.1-3

*Based on von Willebrand factor and factor VIII activity levels. FVIII, coagulation factor VIII; VWF, von Willebrand factor.

wilate® is indicated in adult and pediatric patients with von Willebrand disease for:

On-demand treatment and control of bleeding episodes
Perioperative management of bleeding
Routine prophylaxis to reduce the frequency of bleeding episodes

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII complex

wilate® is made from pooled human plasma that has been collected in GMP-compliant donation centers.

All individual plasma samples undergo extensive testing for viruses, including for HIV, hepatitis A, B and C and parvovirus B199,10

FVIII, factor VIII; GMP, good manufacturing practice; HIV, human immunodeficiency virus; VWF, von Willebrand factor.

wilate® is purified through a series of carefully controlled processing steps, all designed to minimize impurities and ensure viral safety4

Two chromatographic steps ensure high purity and remove non-essential proteins4

Viral safety is achieved by two complementary virus inactivation steps4

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII complex

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII complex

Solvent/detergent treatment4,11,12

A proven and established method used widely in the purification of products made from human plasma
Effective against enveloped viruses, such as HIV, HBV, HCV and West Nile Virus
Inactivates viruses by breaking down the outer layer that surrounds them

Terminal dry heat treatment 
(PermaHeat)4,11,12

Developed to supplement the solvent/detergent process
 
Effective against a broad spectrum of both enveloped and non-enveloped viruses
Uses dry heat (>100°C, for 2 hours) to inactivate viruses

HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII complex

Intact triplet structure of individual multimers | wilate | SHP | 1st Generation | Enhanced proteolysis: pronounced faster migrating band

The manufacturing process of wilate® preserves the structure and multimer distribution of VWF seen in the plasma of healthy individuals4

Figure adapted from Windyga et al. 2011 SHP, standard human plasma.

Size exclusion chromatography

One of the steps in the wilate® purification process is called size exclusion chromatography. This step minimizes impurities and helps reduce the risk of side effects.1,3 When the results of the advanced size exclusion chromatography are analyzed, wilate® shows a single peak (see figure) containing only the native (natural) VWF/FVIII complex.3

wilate shows a single peak containing only the native (natural) VWF/FVIII complex
Competitor Graphic

No albumin is added to wilate®. Added plasma proteins may cause clinical side effects

  • 1

    Srivastava A et al. Haemophilia 2017; 23:264–72.

  • 2

    Windyga J and von Depka-Prondzinski M. Thromb Haemost 2011; 105:1072-9.

  • 3

    Berntorp E and Windyga J. Haemophilia 2009; 15:122–30.

  • 4

    Stadler M et al. Biologicals 2006; 34:281–8.

  • 5

    Kessler CM et al. Thromb Haemost 2011; 106:279–88.

  • 6

    wilate® Full Prescribing Information. Paramus, NJ: Octapharma; rev July 2026.

  • 7

    Sholzberg M et al. TH Open 2021; 5:e264–72.

  • 8

    Octapharma AG, data on file.

  • 9

    Link: Octapharma Quality and Safety, last accessed July 2021.

  • 10

    Link: Octapharma Production Process. last accessed July 2021.

  • 11

    Biesert L and Suhartano H. Vox Sang 1998; 74(Suppl.1):207-12.

  • 12

    Teitel JM. Ann Med 2000; 32:485-92.

Indications and Important Safety Information for wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)].

Please see wilate® full Prescribing Information.

Indication

wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.

Contraindications

Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible
  • Thromboembolic events may occur. Monitor plasma levels of FVIII activity
  • Neutralizing antibodies (inhibitors) to VWF and Factor VIII have occurred following administration of wilate®. Test for neutralizing antibodies if plasma VWF and/or Factor VIII level fail to increase as expected or if bleeding is not controlled after wilate® administration
  • wilate® is made from human plasma and carries the risk of transmitting infectious agents

Adverse Reactions

The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).

Please see wilate® full Prescribing Information.

You Are Now Leaving wilateusa.com

Octapharma does not review, endorse, or control the content of any non-Octapharma site. Octapharma is not responsible for the accuracy, content, practices, or standards of any non-Octapharma resources accessed through a link on this site. Octapharma provides general information for educational purposes. This site does not provide medical advice, diagnosis, or treatment to you. Always consult your physician to help decide a treatment plan or other medical advice.

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created 
for U.S. healthcare professionals (HCPs)

Please see wilate® full Prescribing Information

© 2026 Octapharma USA, Inc. All Rights Reserved WIL-0811.

© 2026 Octapharma USA, Inc. All Rights Reserved WIL-0811.